Drug intelligence / Profile preview

GD-17

Development stage: Preclinical
Lead developer: Tianjin Gudui Biopharmaceutical Technology
Modality: Small Molecules
Administration: Oral

Overview

GD-17 is a preclinical small molecule inhibitor of phosphodiesterase 4 (PDE4) being developed by Gudui BioPharma. PDE4 is an enzyme responsible for the degradation of cyclic adenosine monophosphate (cAMP) in immune and inflammatory cells. By inhibiting PDE4, GD-17 increases intracellular cAMP levels, which leads to the suppression of pro-inflammatory cytokine production (such as TNF-alpha and IL-12) and the promotion of anti-inflammatory mediators. This mechanism is designed to modulate the immune response in chronic inflammatory conditions. The drug is currently being investigated for its potential in treating inflammatory diseases, specifically inflammatory bowel disease (IBD) and multiple sclerosis (MS).

Targets

PDE4 (Phosphodiesterase 4A1)

Beyond the preview

Go deeper on GD-17.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GD-17.

Explore the full profile